Catalog No.
RHJ95302
Species reactivity
Human
Host species
Mouse
Isotype
IgG2a
Clonality
Monoclonal
Tested applications
ELISA: 1:10000, FCM: 1:200-1:400, IF: 1:200-1:500, WB: 1:500-1:2000
Target
CLEC12A, DCAL2, Dendritic cell-associated lectin 2, CLL-1, Myeloid inhibitory C-type lectin-like receptor, C-type lectin domain family 12 member A, CLL1, DCAL-2, C-type lectin-like molecule 1, MICL, CD371
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q5QGZ9
Applications
ELISA, FCM, IF, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.05% Sodium Azide.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
R3Y15
CLEC12A-directed immunocytokine with target cell-restricted IL-15 activity for treatment of acute myeloid leukemia., PMID:40213559
28-color single tube for flow cytometric assessment of myeloid maturation, myeloid neoplasia, and acute myeloid leukemia minimal/measurable residual disease., PMID:40134341
A review of antibody-based immunotherapy clinical trials for adult acute myeloid leukemia (AML): monoclonal antibodies (mAbs) and beyond., PMID:40069930
Recognition and control of neutrophil extracellular trap formation by MICL., PMID:39143217
Crystal structure of the complex of CLEC12A and an antibody that interferes with binding of diverse ligands., PMID:38386511
Twenty-four-color full spectrum flow cytometry panel for minimal residual disease detection in acute myeloid leukemia., PMID:37533738
Flotetuzumab and other T-cell immunotherapies upregulate MHC class II expression on acute myeloid leukemia cells., PMID:36563336
A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL., PMID:35288466
Regulation of the Expression, Oligomerisation and Signaling of the Inhibitory Receptor CLEC12A by Cysteine Residues in the Stalk Region., PMID:34638548
Anti-CD19 CAR T Cells That Secrete a Biparatopic Anti-CLEC12A Bridging Protein Have Potent Activity Against Highly Aggressive Acute Myeloid Leukemia In Vitro and In Vivo., PMID:34253594
Expression of the myeloid inhibitory receptor CLEC12A correlates with disease activity and cytokines in early rheumatoid arthritis., PMID:34045571
A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia., PMID:33617672
Exploring blast composition in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms: CD45RA and CD371 improve diagnostic value of flow cytometry through assessment of myeloblast heterogeneity and stem cell aberrancy., PMID:33369070
Expression of putative leukemia stem cell targets in genetically-defined acute myeloid leukemia subtypes., PMID:33220589
A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells., PMID:33097838
Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in AML and CML., PMID:33085758
Reduced polyfunctional T cells and increased cellular activation markers in adult allergy patients reporting adverse reactions to food., PMID:32698761
Chikungunya Virus Evades Antiviral CD8+ T Cell Responses To Establish Persistent Infection in Joint-Associated Tissues., PMID:32102875
Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity., PMID:31674143
MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis., PMID:31286786
Targeting CLL-1 for acute myeloid leukemia therapy., PMID:31014360
Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia., PMID:30401586
Preclinical pharmacokinetics and pharmacodynamics of DCLL9718A: An antibody-drug conjugate for the treatment of acute myeloid leukemia., PMID:30183491
CLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia., PMID:30037800
An Anti-CLL-1 Antibody-Drug Conjugate for the Treatment of Acute Myeloid Leukemia., PMID:29959143
Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia., PMID:29077054
Expression profile of novel cell surface molecules on different subsets of human peripheral blood antigen-presenting cells., PMID:27766148
MICL controls inflammation in rheumatoid arthritis., PMID:26275430
Modulation of monosodium urate crystal-induced responses in neutrophils by the myeloid inhibitory C-type lectin-like receptor: potential therapeutic implications., PMID:23837669
The C-type lectin Clec12A present on mouse and human dendritic cells can serve as a target for antigen delivery and enhancement of antibody responses., PMID:19494282
The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells., PMID:17609428
Human MICL (CLEC12A) is differentially glycosylated and is down-regulated following cellular activation., PMID:16838277
For research use only. Not for human or drug use.
